Pfizer Inc. (NYSE:PFE) – Stock analysts at Cantor Fitzgerald increased their FY2020 earnings estimates for Pfizer in a research report issued to clients and investors on Wednesday, October 28th. Cantor Fitzgerald analyst L. Chen now anticipates that the biopharmaceutical company will post earnings per share of $2.88 for the year, up from their previous estimate of $2.85. Cantor Fitzgerald also issued estimates for Pfizer’s FY2021 earnings at $3.19 EPS.
Several other brokerages have also recently commented on PFE. SVB Leerink lifted their price objective on shares of Pfizer from $42.00 to $43.00 and gave the company a “market perform” rating in a research note on Wednesday. ValuEngine cut shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. Morgan Stanley lifted their price objective on shares of Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Atlantic Securities cut shares of Pfizer from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $44.00 to $39.00 in a research note on Monday, October 12th. Finally, Mizuho reiterated a “buy” rating and issued a $43.00 target price on shares of Pfizer in a research note on Tuesday, September 15th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company. Pfizer currently has an average rating of “Hold” and a consensus target price of $39.66.
Shares of NYSE PFE opened at $35.28 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. Pfizer has a 12 month low of $27.88 and a 12 month high of $40.97. The company has a 50 day simple moving average of $36.74 and a two-hundred day simple moving average of $36.59. The stock has a market cap of $196.05 billion, a price-to-earnings ratio of 14.00, a PEG ratio of 3.10 and a beta of 0.66.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.01. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The company had revenue of $12.13 billion during the quarter, compared to analysts’ expectations of $12.30 billion. During the same period last year, the business earned $0.75 EPS. Pfizer’s revenue for the quarter was down 4.3% on a year-over-year basis.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be issued a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 4.31%. The ex-dividend date is Thursday, November 5th. Pfizer’s payout ratio is presently 51.53%.
In other Pfizer news, major shareholder Pfizer Inc bought 1,200,000 shares of the company’s stock in a transaction dated Tuesday, October 27th. The stock was acquired at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the acquisition, the insider now directly owns 27,349,211 shares of the company’s stock, valued at $273,492,110. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronald E. Blaylock bought 13,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were acquired at an average cost of $38.55 per share, with a total value of $501,150.00. Following the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at $154,200. The disclosure for this purchase can be found here. 0.08% of the stock is currently owned by insiders.
Several hedge funds have recently made changes to their positions in PFE. Corbett Road Capital Management LLC acquired a new position in shares of Pfizer during the 2nd quarter valued at about $25,000. Reitz Capital Advisors LLC acquired a new position in shares of Pfizer during the 2nd quarter valued at about $29,000. Rocky Mountain Advisers LLC boosted its position in shares of Pfizer by 847.5% during the 2nd quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,000 shares during the last quarter. JJJ Advisors Inc. acquired a new position in shares of Pfizer during the 2nd quarter valued at about $44,000. Finally, NuWave Investment Management LLC boosted its position in shares of Pfizer by 439.7% during the 3rd quarter. NuWave Investment Management LLC now owns 1,468 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,196 shares during the last quarter. 69.08% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Growth and Income Funds
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.